12967_2018_1668_MOESM2_ESM.docx (15.16 kB)
MOESM2 of Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma
journal contribution
posted on 2018-10-24, 05:00 authored by David Borg, Anna Larsson, Charlotta Hedner, Bjรถrn Nodin, Anders Johnsson, Karin JirstrรถmAdditional file 2: Table S2. Correlation and conversion of PODXL expression between paired tissue samples in the neoadjuvant cohort.